Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;145(2):148-155.
doi: 10.1017/S0031182017000506. Epub 2017 May 10.

The antifungal Aureobasidin A and an analogue are active against the protozoan parasite Toxoplasma gondii but do not inhibit sphingolipid biosynthesis

Affiliations

The antifungal Aureobasidin A and an analogue are active against the protozoan parasite Toxoplasma gondii but do not inhibit sphingolipid biosynthesis

A Q I Alqaisi et al. Parasitology. 2018 Feb.

Erratum in

Abstract

Toxoplasma gondii is an obligate intracellular protozoan parasite of the phylum Apicomplexa, and toxoplasmosis is an important disease of both humans and economically important animals. With a limited array of drugs available there is a need to identify new therapeutic compounds. Aureobasidin A (AbA) is an antifungal that targets the essential inositol phosphorylceramide (IPC, sphingolipid) synthase in pathogenic fungi. This natural cyclic depsipeptide also inhibits Toxoplasma proliforation, with the protozoan IPC synthase orthologue proposed as the target. The data presented here show that neither AbA nor an analogue (Compound 20), target the protozoan IPC synthase orthologue or total parasite sphingolipid synthesis. However, further analyses confirm that AbA exhibits significant activity against the proliferative tachyzoite form of Toxoplasma, and Compound 20, whilst effective, has reduced efficacy. This difference was more evident on analyses of the direct effect of these compounds against isolated Toxoplasma, indicating that AbA is rapidly microbicidal. Importantly, the possibility of targeting the encysted, bradyzoite, form of the parasite with AbA and Compound 20 was demonstrated, indicating that this class of compounds may provide the basis for the first effective treatment for chronic toxoplasmosis.

Keywords: Toxoplasma; Aureobasidin A; bradyzoite; sphingolipid biosynthesis.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The structures of the cyclic depsipeptide compounds Aureobasidin A and its analogue Compound 20 (Wuts et al. 2015).
Fig. 2.
Fig. 2.
ED50 of Aureobasidin A (AbA, A-D) or Compound 20 (Cpmd 20, E-H) – μg mL−1; (95% Confidence Interval) – against the Toxoplasma RH tachyzoite form in HFF cells. 6 days post addition of the compounds. In agreement with Sonda et al. (2005), both compounds were non-toxic to HHF cells under the conditions employed. A and B: no wash out post-compound addition; C and D: wash out 2 h post-compound addition; E and F: wash out 8 h post-compound addition; G and H: 2 h pre-treatment of isolated parasites pre-infection. Calculated using GraphPad Prism 7, log(inhibitor) vs normalized response – Variable slope. >10 µg mL−1 – ED50 could not be determined. Representative in triplicate dataset.
Fig. 3.
Fig. 3.
Yeast dependent on the expression of the Toxoplasma AUR1p orthologue TgSLS (YPH499-HIS-GAL-AUR1 pRS426 TgSLS) are resistant to Aureobasidin A (AbA) and Compound 20 (Cmpd 20) at 5 and 10 µg mL−1. This contrasts to the sensitivity of yeast dependent on AUR1 expression (YPH499-HIS-GAL-AUR1 pRS426 AUR1).
Fig. 4.
Fig. 4.
Vero cells (Host), isolated Toxoplasma tachyzoites (Toxo) and Saccharomyces cerevisiae (Yeast), labelled for 1 h with NBD-C6-ceramide and complex sphingolipids then fractionated by HPTLC. Like the host cells, Toxoplasma parasites synthesize sphingomyelin (SM) and ethanolamine phosphorylceramide (EPC), two unique sphingolipids are also produced (X and Y). However, unlike in S. cerevisiae, no labelled inositol phosphorylceramide (IPC) is evident from either host or Toxoplasma cells. Representative dataset.
Fig. 5.
Fig. 5.
Isolated Toxoplasma tachyzoites treated with Aureobasidin A (AbA) and Compound 20 (Cmpd 20) at 10 µg mL−1 for 1 (A), 4 (B) and 7 (C) hours before labelling with NBD-C6-ceramide for 1 h. Neither compound affected the complex sphingolipid profile synthesized at any time point when compared with the vehicle control (DMSO). SM – Sphingomyelin (SM); EPC – Ethanolamine PhosphorylCeramide; X and Y – Unclassified sphingolipids. Representative dataset.
Fig. 6.
Fig. 6.
ED50 of Aureobasidin A (A, AbA) or Compound 20 (B, Cpmd 20) – μg mL−1 (95% Confidence Interval) – against the Toxoplasma Pru bradyzoite form in Human Foreskin Fibroblast (HFF) cells. Three days post addition of the compounds. In agreement with Sonda et al. (2005), both compounds were non-toxic to HHF cells under the conditions employed. Calculated using GraphPad Prism 7, log(inhibitor) vs normalized response – Variable slope. Representative in triplicate dataset.

Similar articles

Cited by

References

    1. Aeed P. A., Young C. L., Nagiec M. M. and Elhammer A. P. (2009). Inhibition of inositol phosphorylceramide synthase by the cyclic peptide Aureobasidin A. Antimicrobial Agents and Chemotherapy 53, 496–504. - PMC - PubMed
    1. Antczak M., Dzitko K. and Dlugonska H. (2016). Human toxoplasmosis-Searching for novel chemotherapeutics. Biomedicine and Pharmacotherapy 82, 677–684. - PubMed
    1. Azzouz N., Rauscher B., Gerold P., Cesbron-Delauw M. F., Dubremetz J. F. and Schwarz R. T. (2002). Evidence for de novo sphingolipid biosynthesis in Toxoplasma gondii. International Journal for Parasitology 32, 677–684. - PubMed
    1. Cerantola V., Guillas I., Roubaty C., Vionnet C., Uldry D., Knudsen J. and Conzelmann A. (2009). Aureobasidin A arrests growth of yeast cells through both ceramide intoxication and deprivation of essential inositolphosphorylceramides. Molecular Microbiology 71, 1523–1537. - PubMed
    1. Chowdhury M. N. (1986). Toxoplasmosis: a review. Journal of Medicine 17, 373–396. - PubMed

Publication types

MeSH terms